DURECT Corporation - Drug delivery technologies treating chronic debilitating disease

Board of Directors

Corporate Policies/Governance

Driving Directions

Development Pipeline

Commercial Products

Research Programs

Business Development Approach

The SABER™ Delivery System

ORADUR® Gel-Cap System

TRANSDUR™ Transdermal Technology System

DURIN™ System

MICRODUR™ System

Localized Drug Delivery

Stock Information

Corporate Presentation

Earnings Estimate

Analyst Coverage

Financial Reports

Information Request

Benefits Overview

Attention Recruiters

About DURECT

Products

Business Development

Science & Technologies

Investor Relations

Careers

News

DURECT: Developing products to treat chronic debilitating disease and technologies that enable biotechnology products.

DURECT Featured Clinical Products

Latest News

TRANSDUR Sufentanil

Indication:

Focus:

Chronic Pain

TRANSDUR™ Sufentanil
A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.

Learn more
View complete product pipeline

March 01, 2010
DURECT to Present at the Cowen and Company Healthcare Conference

February 24, 2010
DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results

February 22, 2010
DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory

	2008 Annual Report
	2007 Annual Report
	2006 Annual Report
	2005 Annual Report

© 2000-2010 DURECT Corporation

Last updated: December 21, 2009
built@zoomedia.com

Contact